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Clinical Question 
Are there long-term detrimental effects of soy protein-based formula in full-term infants? 
Evidence-Based Answer 
There are no significant long-term detrimental effects associated with the use of currently 
available, commercially produced, isolated soy protein-based formula in full-term infants. 
(Strength of Recommendation: B, based primarily on cohort studies). The number of well-
controlled, long-term studies is limited. 
Evidence Summary 
Isolated soy protein-based formulas represent approximately 25 percent of the market share of 
infant formulas sold in the United States. They are approved by the U.S. Food and Drug 
Administration (FDA) to give to full-term infants. Since the first modern use of soy protein-
based formula in 1909, changes have been made to improve safety and nutritional effectiveness. 
In 1976, the American Academy of Pediatrics (AAP) Committee on Nutrition established 
content specifications for soy protein-based formulas; those on the market today meet current 
requirements for vitamins, minerals, and electrolyte content.1 
No large randomized controlled trials were found that evaluated potential long-term detrimental 
effects of soy protein-based formula. Current recommendations are based on extrapolation from 
limited data and observational studies. A search found studies with samples ranging in size from 
five to 811 participants. Several potential adverse effects have been evaluated (Table 1).2-8 
Table 1. Adverse Effects of Soy Protein-Based Formula 
Outcome studied Findings Study design 
Bone mineralization2 No detrimental effects Prospective cohort 
Calcium phosphate 
deficiency2,3 
No detrimental effects Structured review; prospective 
cohort 
Cognitive development3 No detrimental effects Structured review 
Dysmenorrhea4 Slight increase in pain 
score 
Historical cohort 
Growth3 No detrimental effects Structured review 
Immune cell populations5 No detrimental effects RCT 
Menstrual duration4 Slight increase in 
duration 
Historical cohort 
Nutritional status3,6 No detrimental effects Structured review; systematic 
review of RCTs 
Protein metabolism3 No detrimental effects Structured review 
Response to vaccines7 No detrimental effects RCT 
Sensitization allergy6,8 No detrimental effects RCT; systematic review of RCTs 
Thyroid effects3 No detrimental effects Structured review 
Visual acuity3 No detrimental effects Structured review 
 
RCT = randomized controlled trial. 
Information from references 2 through 8. 
The Center for the Evaluation of Risks to Human Reproduction selected soy protein-based 
formula for further evaluation because of public concern about possible health effects.9 This 
joint program of the Centers for Disease Control and Prevention, the FDA, and the National 
Institutes of Health evaluates agents of public health concern by developing and applying tools 
of modern toxicology and molecular biology. For this evaluation, a 14-member panel of 
government and nongovernment scientists from diverse disciplines (including family medicine, 
pediatrics, neonatology, toxicology, and other basic sciences) were selected to evaluate the data. 
The panel reviewed 229 studies, including 38 studies on the effects of soy protein-based 
formulas on human health, provided by an unspecified search methodology. Using a consensus 
approach, the expert panel concluded that the human studies were of limited utility in evaluating 
possible adverse effects of soy formula on reproduction and development because of poor study 
design, lack of experimental detail, or small sample size. Although no long-term detrimental 
effects to growth or sexual maturation were identified, the panel failed to issue a conclusive 
recommendation because of the lack of quality data.9 
We identified only one study that specifically addressed the long-term effects of soy protein-
based formula. It was a historical cohort study of adults who were 20 to 34 years of age and had 
previously participated in a controlled feeding study from 1965 to 1978 (248 participants 
received soy protein-based formula, and 563 received cow's milk). There was no association 
between exposure to soy protein-based formula and general health or reproductive outcomes. 
There was a correlation between receiving soy protein-based formula as an infant and an 
increased duration of menstrual bleeding later in life (adjusted mean difference, 0.37 days; 95% 
confidence interval [CI], 0.06 to 0.68; P = .02). Greater menstrual discomfort (unadjusted 
relative risk for extreme discomfort versus no or mild pain, 1.77; 95% CI, 1.04 to 3.00; P = .04) 
was also reported.4 Several confounding variables were not controlled for in the original feeding 
study, including the use of older soy protein-based formulations, which limits the applicability of 
the findings to current formulas.4 
Recommendations from Others 
The American Academy of Family Physicians (AAFP) and the AAP recommend the use of 
breast milk exclusively for at least the first six months of life.1,10 The AAP recommends that, 
for full-term infants whose nutritional needs are not being met from maternal breast milk or cow 
milk-based formulas, soy protein-based formula is a safe and effective alternative.1 The AAFP 
has no current policy recommendation regarding the use of soy protein-based formula. 
Clinical Commentary 
Parents often consult physicians regarding how best to feed their infants. These decisions can be 
complicated by many factors, including nutritional information, bonding, convenience, and 
advice from others. Although it is helpful to know that no detrimental effects were associated 
with soy protein-based formula compared with cow milk-based formula, no information 
comparing it with breast milk was included. Because breastfeeding is the preferred infant feeding 
method for the first six months of life and because it has shown clear benefits over any type of 
formula feeding, this comparison is vital when counseling parents. 
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